Air Microfluidic Systems Inc. (AMS)
Air Microfluidic Systems Inc. (AMS) is a startup working on developing wearable devices powered by our patent-pending air microfluidics technologies. Our current leading product is an air microfluidics-enabled active compression apparel (AMACA) for treating breast cancer-related lymphedema, which has the state-of-the-art performance while being portable with a smartphone-sized wearable control box. AMACA is at Technology Readiness Level (TRL) 5. We are at the pre-clinical stage focusing on the research and development of AMACA. The proceeds will be used for research and development from the current TRL 5 to TRL 7, pre-clinical trials (TRL 8), and commercialization (TRL 9).
Hear more from this company during the Early Technology Showcase.
Presenter: Run Ze Gao
Read More
Denote
Denote Therapeutics is developing the allogeneic Double Negative T-cell (DNT) platform for off-the-shelf therapeutics in oncology and certain immune disorders. Denote plans to advance this platform through the development of both unmodified and modified DNT therapies both in-house and in conjunction with partners.
Hear more from this company during the Early Technology Showcase.
Presenter: Robert Verhagen, CEO
Read More
DNAMx
DNAMx is a cross-border molecular diagnostics start-up company being spun out of University Health Network. Scientific co-founders from Princess Margaret Cancer Research Institute, Daniel De Carvalho (Interim CSO) and Scott Bratman (CEO), have joined forces with serial entrepreneurs, Anne-Renee Hartman (CMO), David Scheer (Board Chair), and Maneesh Jain (Board Member), to commercialized cutting-edge liquid biopsy technology for cancer detection and management. Building on multiple high-impact publications in Nature and Nature Medicine, DNAMx is now raising a large Series A financing round to achieve ambitious milestones aimed at bringing the technology into the clinic.
Hear more from this company during the Early Technology Showcase.
Presenter: Scott Bratman, Founder & CEO
Read More
Feldan Therapeutics
Feldan Therapeutics is a biotechnology company that introduced the Feldan Shuttle, a peptide-based platform that allows safe and efficient delivery of proteins, peptides and small molecules inside cells. This technology has the potential to help treat many diseases by targeting intracellular pathways. Feldan is focused on bringing its two therapeutic applications (topical product for BCC/Gorlin patients and inhaled CRISPR-based therapy for Cystic Fibrosis) to the clinic. The company is looking to raise its Series B round of financing mid-2021 to finance Phase I/II clinical trial of our first-to-human indication (Gorlin syndrome) as well as the pre-clinical phase of our Cystic Fibrosis indication.
Presenter: Francois-Thomas Michaud, Chief Executive Officer
Read More
Huron Digital Pathology
With a first-of-its-kind, AI-enabled image search engine called Lagotto, Huron Digital Pathology is revolutionizing how pathologists access the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data, to drive efficiency and reduce diagnostic error. We just gained our first high profile customer for Lagotto in the US and are beginning to generate recurring software revenue. We are actively engaging with large hospitals and institutions keen to benefit from our solution. We are raising a Series A round to scale our sales efforts, expand our product portfolio and achieve regulatory approvals.
Presenter: Patrick Myles, Chief Executive Officer
Read More
Innovakine
Using cutting-edge protein and cell engineering approaches, Innovakine has developed a proprietary platform technology that allows clinicians to send exclusive, customized signals to immune cells and other cell types anywhere in the body, with broad clinical applications in the fields of cancer immunotherapy, infectious disease, autoimmunity, transplantation and regenerative medicine. Innovakine was founded in 2019 by Brad Nelson PhD (Distinguished Scientist, British Columbia Cancer; Professor, UBC) and Martin Boulanger PhD (Professor, University of Victoria) following a successful research collaboration with Zymeworks Inc., a clinical-stage biotechnology company. Innovakine is raising $4M in seed funding to complete pre-clinical POC studies in murine solid tumor models.
Presenter: Brad Nelson, Co-founder and CEO
Read More
IntelliStem
IntelliStem is an early stage biotech company that has created the next generation of cell therapy products to target catastrophic diseases such as cancer and Infectious diseases. Its first product “Super Sentinel CellsTM” is an off-the-shelf product to target cancer that has shown an 80% success rate compared to 20% of incumbents In-vivo, which can target both blood and solid tumors offering scalable and more efficacious solutions, at a fraction of the cost of the current platforms. We hope to use investor funds to advance our assets to market through clinical trials, then out-licensing and co-development.
Presenter: Riam Shammaa, Chief Executive Officer and Co-Founder
Read More
Jenthera Therapeutics
Jenthera Therapeutics is a seed stage therapeutics company introducing a novel protein-based gene editing platform delivering solutions to the major challenges currently facing CRISPR therapeutics: safety, precision corrections and targeted delivery. Our patented technology allows for the rapid development of high efficacy non-viral gene editing complexes achieving unprecedented levels of efficiency in cellular delivery, high frequencies of corrective precision repair and safety from off-target effects. We are looking to raise a 2M$ seed round to finance our EML4-ALK non-small cell lung cancer in vivo validation leading to a Series A in Q4-2021 that will fund IND enabling preclinical studies and PhaseI/II clinical trials.
Presenter: Philip Roche, CEO
Read More
Mobio Interactive
Mobio Interactive is a revenue-generating digital therapeutics company that develops and commercializes clinically validated and objectively quantified software to prevent, measure and treat mental illness. Mobio’s recent progress includes completion of a clinical trial with cancer patients, demonstrating equivalent effect sizes on psychological wellbeing from the DTx Am Mindfulness as compared to group psychotherapy. Mobio is raising Series A capital to support clinical trials, IP protection, payor & partner negotiations, regulatory approval, and DTx sales.
Presenter: Bechara Saab, CEO
Read More
Nanovista Inc.
Nanovista is developing novel imaging agents for surgical oncology with the lead product, CF800, enabling cancer surgeons to visualize tumors in real time during surgery. Even the most skilled surgeons capture as little as 30-60% of the tumor margins in challenging disease areas. Nanovista's CF800 liposomal imaging agent accumulates specifically at tumor margins and is ideally suited to visualize all solid tumors. CF800 works with existing operating room near-infrared imaging equipment and illuminates tumors both at the surgery planning phase and inside the operating room, with the potential to significantly improve cancer surgery outcomes. The company is raising capital for Phase I development of CF800 in lung cancer and head and neck cancer.
Presenter: Anton Neschadim, Chief Executive
Read More
Orion Biotechnology Canada
Orion Biotechnology is a clinical stage biotechnology company developing GPCR-targeted therapeutics for the treatment of cancer and other serious diseases. This novel scientific approach is enabled by Orion’s proprietary high-throughput drug discovery platform. Our disruptive analog-based technologies position OB to become a premier GPCR-focused company to deliver next generation therapeutics not only for Orion’s pipeline, but also in collaboration with other biopharmaceutical companies. We plan to advance our lead candidate into Phase 1b/2a trial in Oncology and complete lead optimization of 2 additional drug candidates.
Presenter: Antaole Klepatskyi, COO
Read More
Ovensa Inc.
Ovensa Inc. is a preclinical stage biotech company advancing its siRNA lead candidate silencing galectin-1 (Gal-1) overexpression in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors as a combination therapy in head & neck cancer. Ovensa currently works with pharmaceutical companies to formulate their drugs into nanoparticles using Ovensa's TRIOZAN™ drug delivery platform. Most of the collaborations are related to siRNA or mRNA therapeutics where Ovensa offers a non-lipidic approach for intranasal, IV or vaccines delivery.
Presenter: Stephane Gagne, President & CEO
Read More
Rna Diagnostics
Rna Diagnostics is a clinical-stage company developing it’s first product, a proprietary diagnostic test for breast cancer therapy response measurement. Our test will indicate to doctors, early in treatment, which patients will receive a survival benefit and which patients will not. This test will help address the $60 billion that is spent each year on cancer drugs that are not working for a majority of patients.
Presenter: Jeremy Bridge-Cook, President & CEO
Read More
Specific Biologics
Specific Biologics is a discovery stage company developing platform gene editing technologies as therapeutics to treat or cure disease through precision gene editing. Our gene editor Dualase is designed to overcome two problems with current gene editor – random DNA insertions / deletions and low frequency repair. Unlike other technologies, Dualase cuts DNA in two spots and leaves non-compatible DNA ends. These ends create precise deletions to disrupt DNA or increase rates of repair to correct DNA. We are raising $2.7 million CAD to advance our programs in cystic fibrosis and oncology in preclinical animal models and further develop the platform.
Presenter: Brent Stead, CEO
Read More
TATUM Bioscience
TATUM Bioscience is a synthetic biology startup developing a new class of drug called synthetic live biotherapeutics (synLBT). synLBT are probiotics engineered to execute advanced therapeutic tasks. This technology disrupts the conventional drug development process by allowing us to build drugs instead of discovering them. Using its unique modular platform, TATUM design synLBTs to tackle diseases for which conventional drugs have now reached their limits and focuses its efforts on antibiotic resistance and oncology. The company will open a seed round in Q4 of 2021 to advance its programs, expand its IP portfolio, and conduct INTERACT and pre-IND meetings.
Presenter: Jean-François Millau, CEO
Read More
TCRyption Inc.
TCRyption Inc., a novel TCR-T cell therapy company, with the goal of expanding the availability of T-cell receptor based cellular therapeutic (TCR-T) options as effective and safe therapies across multiple cancers with a high unmet need. The company’s highly diverse and growing TCR bank utilizes the proprietary TCRypt platform, originally created by Dr. Naoto Hirano at University Health Network’s (UHN) Princess Margaret Cancer Centre. With unparalleled sensitivity in its ability to mine physiologically relevant TCR’s, this platform enables the rapid discovery of an expansive bank of TCRs that can be used to better address patient needs. TCRyption was established with an initial $10 million in seed financing from TIO Bioventures.
Presenter: Michael Tusche, Co-CEO
Read More
Treadwell Therapeutics
Treadwell Therapeutics is a clinical stage Biotechnology company, driven by novel science, and focused on the development of First in class, best in class or only in class small molecule candidates for unmet needs in oncology. Co-Founded in July of 2019 by Drs. Tak Mak and Mark Bray, Treadwell’s three clinical stage assets have been in development for over a decade by the Therapeutics group at the Campbell Family Institute at UHN. With operations in New York, Boston, San Francisco, Hong Kong, and a substantial footprint in Toronto, Treadwell has a global view and strong local roots. The company was established with a $25M investment from TIO Bioventures.
Presenter: Michael Tusche, Co-CEO
Read More
Virica
At Virica, we believe that viral medicines hold the key to unlocking the future of human healthcare. However, there are unmet needs in the field of viral therapeutics that limit their development and scalability. Virica fills this void through our proprietary viral sensitizer or VSE technology, in order to realize the promise of viral medicines to extend the horizons of human healthcare. We deploy and monetize our versatile VSE small molecules by working with vaccine and gene therapy manufacturers to reduce their cost of goods, and by developing a pipeline of enhanced viral therapeutics for cancer and other diseases.
Presenter: Jean-Simon Diallo, Scientific Founder/CEO
Read More
